The recent security compromise within the New York City Health and Hospitals system has sent
Ivan Kairatov stands at the forefront of biopharmaceutical innovation, possessing an intricate
Ivan Kairatov is a seasoned biopharma expert with an extensive background in the research and development of transformative genetic medicines. Having spent years navigating the complexities of viral vector technology and the rigorous demands of clinical trials, he offers a deep technical
The difference between survival and fatality in sudden cardiac arrest (SCA) is often measured in seconds, yet the medical community has historically lacked the tools to see the storm gathering before it breaks. For decades, the unpredictability of SCA has been its most lethal characteristic,
The rapid acceleration of medical breakthroughs in recent years has transformed clinical trials
Ivan Kairatov is a distinguished biopharma expert with a career dedicated to the intersection of
The biopharmaceutical sector is entering a new era. After last year's market disruptions, the industry faces a harsh truth: scientific breakthroughs alone are no longer enough to keep ahead of the…
The pharmaceutical sector is entering a decisive phase as obesity therapeutics gain more ground as
Advanced Therapy Medicinal Products cannot be scaled the same way biologics were. The core
The End of the Old Biopharma Playbook The biopharmaceutical industry is confronting a structural
By 2030, the tissue-engineering market is projected to exceed $32.45 billion , reflecting a
The pharmaceutical industry has long grappled with the overwhelming complexity of human biology, where the cost and time required to bring a single therapeutic candidate to market often exceed the financial capabilities of all but the largest global entities. Traditional drug discovery has
The transition from traditional paper charts to sophisticated digital health ecosystems has
For millions of women worldwide, the journey toward an endometriosis diagnosis has historically
